Psychedelic Spotlight News

  • The Road to Psychedelics Legalization

    Act, Policy

    Matthew X. Lowe, Ph.D., the Research Director of Unlimited Sciences, explains why observational research is the key for eventual legalization of psychedelic drugs.

  • How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more

    Listen, Videos

    How long until Psychedelic Stocks Payoff?🍄🚀

    To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

    And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

    In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

    Or, translated to Reddit-speak: when moon?

    To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

    There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

    The first will happen relatively soon.

    #PsychedelicStocks #MindMed #Cybin

  • Interview with Dr. Erica Zelfand

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.